Betting and Winning: SCOTUS Decision Underscores High Stakes In Pharma’s Strategy
This article was originally published in RPM Report
Executive Summary
The Supreme Court decision was a decisive victory for the biopharma industry for a number of reasons. But the drama that unfolded in a razor-close decision will continue as new milestones—political and legislative—approach.
You may also be interested in...
King v. Burwell Ruling Clears A Path For “Cures,” Avoids Disrupting ACA
The pharmaceutical industry didn’t have as much at stake in the second major Supreme Court ruling on the Affordable Care Act – but should still be celebrating the decision to upheld the Administration’s approach to exchanges.
Medicaid Expansion: Can Texas Be Turned?
Visits from HHS Secretary Sebelius raise the question of whether Texas could change its mind and expand Medicaid eligibility under the ACA.
Medicaid Expansion: Glass Half Full for Biopharma
Most health reform watchers have been tracking state votes on Medicaid expansion as a sort of scorecard on whether Obama Administration is winning or losing in health care reform. Push back from the states is making news now, but for biopharma sponsors, even a glass half full is a positive—and the long-term outlook is even brighter.